Overview

Glucagon Ready-to-Use for the Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1D

Status:
Completed
Trial end date:
2020-03-23
Target enrollment:
Participant gender:
Summary
This study is a randomized, placebo-controlled, double-blind, two-treatment, two-period, crossover comparison in a clinical research center (CRC) setting, followed by a randomized, placebo-controlled, partially double-blinded, 3-arm parallel comparison in an outpatient setting to evaluate the preliminary efficacy and safety of Glucagon Ready-to-Use (RTU) to prevent exercise-induced hypoglycemia (EIH) in adults with Type 1 diabetes mellitus (T1D), who perform regular, moderate-to-high intensity aerobic exercise.
Phase:
Phase 2
Details
Lead Sponsor:
Xeris Pharmaceuticals
Treatments:
Glucagon
Glucagon-Like Peptide 1
Insulin